Dissemin is shutting down on January 1st, 2025

Published in

Future Medicine, Biomarkers in Medicine, 10(8), p. 1207-1217, 2014

DOI: 10.2217/bmm.14.90

Links

Tools

Export citation

Search in Google Scholar

The identification of three novel biomarkers of major adverse kidney events

This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Green circle
Postprint: archiving allowed
Green circle
Published version: archiving allowed
Data provided by SHERPA/RoMEO

Abstract

Aim: To describe the prognostic value of three novel biomarkers for acute adverse kidney events compared with routine biological markers. Material & methods: We used high-end MS to quantify biomarkers predictive of acute kidney injury (AKI) and major adverse kidney events (MAKE) in 100 adult patients after open heart surgery (n = 100). Results: Early postoperatively measured LG3 (a C-terminal fragment of perlecan), LTBP2 (latent transforming growth factor binding protein-2), Cathepsin L as well as two other renal biomarkers (NGAL, Cystatin C) had greater predictive value for AKI (n = 23) and MAKE (n = 24) compared with creatinine, urea and urine output. Conclusions: LG3, LTBP2 and Cathepsin L deserve further exploration as biomarkers for the early identification of patients at risk of MAKE.